Literature DB >> 11276391

The adrenal and the metabolic syndrome.

M S Golub1.   

Abstract

This review discusses the possible interrelationships between adrenal steroid hormones and the metabolic syndrome. Abnormal regulation of the hypothalamic-pituitary-adrenal axis has been proposed. Studies in the United Kingdom associated the metabolic syndrome with low birth weight and hyperactivity of the entire axis. In Italy, increased pituitary responsiveness to stimulation with vasopressin and corticotrophin-releasing hormone was demonstrated in women with central obesity. Swedish researchers have reported that increased stress responses of the axis correlated with a less variable but decreased cortisol level. An allele of the glucocorticoid receptor was also associated with various components of the metabolic syndrome. Evidence also suggests that central obesity is associated with an increased peripheral conversion of cortisol to cortisone and subsequent feedback stimulation of the axis. On the other hand, central fat may have an increased local metabolism in the direction of cortisol. Roles for dehydroepiandrosterone and aldosterone in the syndrome have also been proposed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276391     DOI: 10.1007/s11906-001-0022-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  22 in total

1.  Does central obesity reflect "Cushing's disease of the omentum"?

Authors:  I J Bujalska; S Kumar; P M Stewart
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

2.  Reduced serum dehydroepiandrosterone levels in diabetic patients with hyperinsulinaemia.

Authors:  Y Yamaguchi; S Tanaka; T Yamakawa; M Kimura; K Ukawa; Y Yamada; M Ishihara; H Sekihara
Journal:  Clin Endocrinol (Oxf)       Date:  1998-09       Impact factor: 3.478

3.  Low birth weight predicts elevated plasma cortisol concentrations in adults from 3 populations.

Authors:  D I Phillips; B R Walker; R M Reynolds; D E Flanagan; P J Wood; C Osmond; D J Barker; C B Whorwood
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

Review 4.  Pituitary incidentalomas.

Authors:  D C Aron; T A Howlett
Journal:  Endocrinol Metab Clin North Am       Date:  2000-03       Impact factor: 4.741

Review 5.  Glucocorticoids and insulin resistance: old hormones, new targets.

Authors:  R C Andrews; B R Walker
Journal:  Clin Sci (Lond)       Date:  1999-05       Impact factor: 6.124

6.  A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension.

Authors:  M Suzuki; A Kanazawa; M Hasegawa; Y Hattori; Y Harano
Journal:  Endocr J       Date:  1999-08       Impact factor: 2.349

7.  Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans.

Authors:  T L Goodfriend; B M Egan; D E Kelley
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1999 May-Jun       Impact factor: 4.006

Review 8.  Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome?

Authors:  D I Phillips; D J Barker; C H Fall; J R Seckl; C B Whorwood; P J Wood; B R Walker
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

9.  Sexual dimorphism in 11 beta hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects.

Authors:  J U Weaver; N F Taylor; J P Monson; P J Wood; W F Kelly
Journal:  Clin Endocrinol (Oxf)       Date:  1998-07       Impact factor: 3.478

10.  The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.

Authors:  R Pasquali; S Cantobelli; F Casimirri; M Capelli; L Bortoluzzi; R Flamia; A M Labate; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1993-08       Impact factor: 5.958

View more
  1 in total

1.  More on adrenal activity in the metabolic syndrome.

Authors:  Michael L Tuck; Dalila B Corry
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.